-

Circle Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced that David J. Earp, J.D., Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:00 p.m. PT.

Dr. Earp will provide an overview of the company’s pipeline, including CID-078, a first-in-class oral macrocyclic cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors, and CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, with potential applications in malignancies, including ER-positive breast cancer and lymphomas.

About Circle Pharma

Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

Circle Pharma, Inc.,


Release Versions

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

More News From Circle Pharma, Inc.,

Circle Pharma Announces Participation in November Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced management will participate in two upcoming investor conferences in November:Stifel 2026 Healthcare ConferencePresentation: Thursday, November 12, 2026, 1:30 p.m. ETParticipants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officerLocation: New York, N...

Circle Pharma Strengthens Leadership Team with Promotion of Marie Evangelista, Ph.D., to Chief Scientific Officer and Addition of Mary Ellen Sillivos as SVP and Head of Human Resources

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the promotion of Marie Evangelista, Ph.D., to chief scientific officer and the appointment of Mary Ellen Sillivos as senior vice president and head of human resources. The appointments strengthen Circle’s leadership team as the company advances its pipeline of next-generation targeted macrocycle ther...

Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an oversubscribed $92.5 million Series E financing. The financing was led by The Column Group and included participation from other existing and new investors including Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company. Proceeds from the financing will drive the advan...
Back to Newsroom